Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotech firm Anadis has signed a final agreement with ImmuCell. Under the terms of the agreement, Anadis has licensed from ImmuCell a portfolio of issued patents, IND filings, clinical data, manufacturing plans and know-how related to several human heath product lines.
Subscribe to our email newsletter
In particular the deal will directly enhance product development work for Clostridium difficile, E.coli and immune deficiency related opportunistic infections. The licensed technologies are all related to the usage of hyperimmune bovine colostrum to provide immediate-acting passive immunity against infectious diseases. The royalty-based deal requires no upfront or milestone payments.
The intellectual property Anadis obtains under this agreement includes, US patent for therapeutic treatment of Clostridium difficile-associated diseases and colonic delivery of protein or peptide compositions.
Zeil Rosenberg, CEO of Anadis, said: “Beyond the issued patents, the clinical work that ImmuCell has successfully completed over many years with the US Navy and Johns Hopkins University and others will expedite Anadis commercial product development to address large unmet human health needs in the US and worldwide.”